Lundbeckfonden Ventures
FoundationCopenhagen · Pre-Seed–Late Stage · 1 people tracked
Investment thesis
Lundbeckfonden aims to bring scientific discoveries to lives by investing actively in both business and science. Toward 2030 it plans to double its regular grants for research in Denmark, build a clearer and more strategic focus on the brain, expand its portfolio of long-term ownership stakes within healthcare, and take concrete initiatives to strengthen collaboration between research and industry.
Source: firm website, verified Aug 3, 2026.
Team · 1 people
from public directories
What they invest in
from 2 of 2 portfolio companiesBiotech ×1Consumer ×1Media & Entertainment ×1Medical Devices ×1Sports Tech ×1
HQs:Vietnam×1
Investments · 2 tracked
founders shown can be your intro pathXoilac TV is a free online football (soccer) live-streaming platform serving fans in Vietnam, offering Full HD match broadcasts of European, Asian, Vietnamese, and international competitions.
ConsumerMedia & EntertainmentSports Tech
Co-investorsAisling CapitalNew Enterprise Associates (NEA)AbingworthPappas CapitalRiverVest Venture Partners
VarmX is developing VMX-C001, a universal bypassing agent designed to restore blood coagulation in patients taking Factor Xa Direct Oral Anticoagulants (FXa-DOACs).
BiotechMedical Devices
Co-investorsSound BioventuresUNIIQYsios CapitalBGVBioGeneration VenturesEIC+2 more
Portfolio news
latest coverage across their companies
Frequently asked questions
- What stage does Lundbeckfonden Ventures invest at?
- Lundbeckfonden Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Lundbeckfonden Ventures focus on?
- Lundbeckfonden Ventures focuses on Biotech, Healthtech, Impact & Social Good, Medical Devices.
- Where is Lundbeckfonden Ventures located?
- Lundbeckfonden Ventures is headquartered in Copenhagen, DK.
- Does Lundbeckfonden Ventures lead rounds?
- Yes, Lundbeckfonden Ventures leads investment rounds.
Images
Similar investors
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
Forbion is a global venture capital firm focused on advancing biotech innovations and sustainable solutions aimed at improving human and planetary health.
LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.